Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lawrence Amato

Internal Medicine Grayslake, IL Medical Doctor

NPI 1528020690 CMS profile 69000

1170 E Belvidere Rd Ste 202, Grayslake, IL 60030

Open in the dashboard

General payments

$16,750

964 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lawrence Amato of Grayslake, IL is reported in the CMS Open Payments database as having received $16,750 across 964 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,773 82
2024 General $2,492 132
2023 General $2,085 119
2022 General $2,751 159
2021 General $2,900 172
2020 General $2,512 142
2019 General $2,237 158

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lawrence Amato
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Lawrence Amato were reported at $1,773. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Lawrence Amato Internal Medicine median Middle half National median
2019 $2,237 $159 $48–$570 $163
2020 $2,512 $119 $33–$402 $114
2021 $2,900 $135 $37–$521 $132
2022 $2,751 $141 $42–$496 $149
2023 $2,085 $149 $45–$519 $160
2024 $2,492 $154 $47–$537 $164
2025 $1,773 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,104 115 payments
  2. AbbVie, Inc. $1,626 108 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,587 83 payments
  4. Amgen Inc. $1,200 65 payments
  5. Novo Nordisk Inc $1,035 54 payments
  6. Pfizer Inc. $755 28 payments
  7. Avanir Pharmaceuticals, Inc. $750 54 payments
  8. Electromed, Inc. $616 47 payments
  9. Amarin Pharma Inc. $570 36 payments
  10. Janssen Pharmaceuticals, Inc $551 28 payments
  11. Other $5,957 346 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,704 960 payments
  2. Education $46 4 payments
Products named General payments · program years 2019–2025
  1. Repatha $987 54 payments
  2. JARDIANCE $889 46 payments
  3. Otezla $758 40 payments
  4. NUEDEXTA $750 54 payments
  5. FARXIGA $720 36 payments
  6. UBRELVY $659 45 payments
  7. SMARTVEST $584 46 payments
  8. Vascepa $551 35 payments
  9. Ozempic $544 28 payments
  10. LINZESS $498 28 payments
  11. Other $15,517 834 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 236 drugs

Part D claims

34,752

Median for Internal Medicine: 777

Drug cost

$1,782,058

Median for Internal Medicine: $73,373

Branded share of claims

16.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 583 $230,287
Jardiance Empagliflozin Brand 248 $165,597
Farxiga Dapagliflozin Propanediol Brand 161 $98,197
Mounjaro Tirzepatide Brand 76 $93,542
Trulicity Dulaglutide Brand 85 $81,528
Xarelto Rivaroxaban Brand 98 $75,661
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 87 $75,184
Januvia Sitagliptin Phosphate Brand 84 $52,253
Ozempic Semaglutide Brand 35 $51,211
Nuedexta Dextromethorphan Hbr/Quinidine Brand 63 $39,204

The 10 drugs with the highest cost, of 236 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$244,004

Of which drugs: $1,413

Medicare patients

499

Average age 77

Services billed

5,139

293 women, 206 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 37%
COPD 30%
Ischemic heart disease 29%
Atrial fibrillation 24%
Depression 22%
Heart failure 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 34 34 $745
Injection, lincomycin hcl, up to 300 mg J2010 Office 17 35 $220
Injection, methylprednisolone acetate, 80 mg J1040 Office 12 12 $61
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 20 $16

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 38 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
$178 — —
AIRSUPRA
$162 — —
TRULANCE
$124 25 —
NEXLETOL
$121 — —
ELIQUIS
$117 583 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 38 with Patron

Records

964 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record